Development of a patient-based grading scale for PedMIDAS

Division of Neurology, Cincinnati Children's Hospital Medical Center, OH 45229-3039, USA.
Cephalalgia (Impact Factor: 4.89). 11/2004; 24(10):844-9. DOI: 10.1111/j.1468-2982.2004.00757.x
Source: PubMed


The objective was to develop and validate a patient-based grading scale for PedMIDAS. PedMIDAS was administered to 329 children, who rated their overall disability based on the adult MIDAS grades. This patient-based rating and PedMIDAS scores were compared to develop the grading scale. Headache disability was rated little to none, 49.5%; mild, 26.7%; moderate, 15.8%; and severe, 7.9%, with PedMIDAS raw scores of 4.9 +/- 6.3, 17.8 +/- 14.9, 40.6 +/- 34.2, and 91.4 +/- 69.8. Convergence of these results yielded an empirically derived grading system: Grade I, 0-10; II, 11-30; III, 31-50 and IV, > 50. Higher grades corresponded to an increased need for prophylactic treatment. A patient-based grading scale further increases the utility of PedMIDAS in assessing migraine disability in children, so that it can be widely used in routine clinical evaluation and management.

28 Reads
  • Source
    • "The measure quantifies headache-related disability during the past three months across school, home, sports and social activities [23,24]. Responses are summed and then graded as reflecting little to none (0 to 10, Grade I), mild (11 to 30, Grade II), moderate (31 to 50, Grade III), and severe disability (greater than 50, Grade IV) [25]. PedMIDAS correlates significantly with frequency, duration, and severity of headache and is sensitive to treatment response. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the efficacy of a self-guided CD-ROM program ("Headstrong") containing cognitive-behavioral self-management strategies versus an educational CD-ROM program for treating headaches, headache-related disability, and quality of life. Participants were 35 children ages 7-12 years with migraine recruited from one university medical center and two children's hospital headache clinics. Participants were randomly assigned to complete the Headstrong or educational control CD-ROM program over a 4-week period. Data on headache frequency, duration, and severity, migraine-related disability, and quality of life (QOL) were obtained at baseline, post-intervention, and 3-months post-intervention. At post-intervention, Headstrong resulted in lower severity (on a 10-point scale) than the control group by child report (5.06 +/- 1.50 SD vs. 6.25 +/- 1.92 SD, p = 0.03, ES = 0.7). At 3-months post-intervention, parents reported less migraine-related disability (on the PedMIDAS) in the Headstrong group compared to the control group (1.36 +/- 2.06 SD vs. 5.18 +/- 6.40 SD; p = 0.04, ES = 0.8). There were no other group differences at post treatment or at 3-months post-intervention. When compared to an educational control, Headstrong resulted in lower pain severity at post-treatment and less migraine-related disability at 3-months post-intervention, by child and parent report respectively. Headache frequency and quality of life did not change more for Headstrong versus control. Additional research is needed on the Headstrong Program to increase its efficacy and to test it with a larger sample recruited from multiple centers simultaneously.
    The Journal of Headache and Pain 02/2014; 15(1):12. DOI:10.1186/1129-2377-15-12 · 2.80 Impact Factor
  • Source
    • "It has been changed according to childhood lifestyle. The questions are concerned with the influence of headache on school performance such as whole day and partial day absences from school, 50% or less school functioning, ability to perform homework and chores and on social abilities such as sports (9,10). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Headache is a common disabling neurological disorder and migraine comprises more than half the causes of recurrent headaches in children. Despite extended prevalence of this type of headache there is lack of evidence about best drug treatment for migraine. So we aimed to compare the therapeutic effects of these drugs on childhood migraine. In the current study, a randomized clinical trial consisting of 78 patients according to 2004 International Headache Association criteria were randomly assigned to two groups that matched by age and sex. One of these two groups was treated with Topiramate, while the other was given Propranolol. After one and four months, the efficiency of these treatments was measured in terms of frequency, severity and duration of migraine attacks. Results obtained from the data collected showed that of these 78 studied patients, 38 patients received Topiramate treatment (group A) and the rest (40 patients; group B) was treated with Propranolol. The average age of group A was 8.5± 2.9 years and that of group B was 8.3 ± 2.8 years. No significant difference was observed between these two groups in terms of reduction in frequency, severity and duration of migraine attacks. Results showed that both treatments had the same efficiency in healing migraine headaches and there was no significant difference between their treating results. However, further studies are needed to examine medical effects of these two medicines.
    03/2013; 7(1):9-14.
  • Source
    • "3. Pediatric Migraine Disability Assessment Scale (PedMIDAS), a standardised validated health-related quality of life scale for children with migraine [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A recent Cochrane Review demonstrated the remarkable lack of reliable clinical trials of migraine treatments for children, especially for the two most prescribed preventative treatments in the UK, Propranolol and Pizotifen. Migraine trials in both children and adults have high placebo responder rates, e.g. of 23%, but for a trial's results to be generalisable "placebo responders" should not be excluded and for a drug to be worthwhile it should be clearly superior, both clinically and statistically, to placebo. Two multicentre, two arm double blind parallel group randomised controlled trials, with allocation ratio of 2:1 for each comparison, Propranolol versus placebo and Pizotifen versus placebo. The trial is designed to test whether Propranolol is superior to placebo and whether Pizotifen is superior to placebo for the prevention of migraine attacks in children aged 5 - 16 years referred to secondary care out-patient settings with frequent migraine (2-6/4 weeks). The primary outcome measure is the number of migraine attacks during trial weeks 11 to 14. A strength of this trial is the participation of clinically well defined migraine patients who will also be approached to help with future longer-term follow-up studies. Trial Registration
    Trials 06/2010; 11(1). DOI:10.1186/1745-6215-11-71 · 1.73 Impact Factor
Show more